

CTD HOLDINGS INC  
Form 8-K  
February 06, 2018  
**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **February 6, 2018**

**CTD HOLDINGS, INC.**

(Exact name of registrant as specified in charter)

**Florida**

(State or other Jurisdiction of Incorporation or  
Organization)

**000-25466**

(Commission File  
Number)

**59-3029743**

(IRS Employer Identification  
No.)

**6714 NW 16th Street, Suite B, Gainesville, Florida 32563**  
(Address of Principal Executive Offices) (zip code)

**386-418-8060**

(Registrant's telephone  
number, including area code)

Edgar Filing: CTD HOLDINGS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01. Other Events**

CTD Holdings, Inc. has obtained preliminary data suggesting that Trappsol® Cyclo™, its proprietary formulation of hydroxypropyl beta cyclodextrin, crosses the blood-brain-barrier in individuals suffering from Niemann-Pick disease type C. Data were derived from initial subjects participating in CTD's phase I clinical trial in the United States ("A Phase I Study to Evaluate the Single- and Multiple-dose Pharmacokinetics of Intravenous Trappsol Cyclo (HPBCD) in Patients with Niemann-Pick Disease Type C (NPC-1) and the Effects of Dosing Upon Biomarkers of NPC Disease," NCT02939547), and phase I/II clinical trial in Europe and Israel ("A Phase I/II Study to Evaluate the Safety and PK of IV Trappsol® Cyclo™ (HPBCD) in Patients with Niemann-Pick Disease Type C and Pharmacodynamic Effects of Treatment Upon Markers of Cholesterol Metabolism and Clinical Outcomes," NCT02912793). Following intravenous administration of Trappsol® Cyclo™ to study subjects, it was detected in subjects' cerebrospinal fluid. The clinical significance of these findings will be determined as part of the final analysis of both clinical trials.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CTD Holdings, Inc.**

Date: February 6, 2018

By: /s/ Jeffrey L. Tate

Jeffrey L. Tate

Chief Operating Officer